Anthony Vendetti, an analyst from Maxim Group, maintained the Buy rating on Electrocore. The associated price target is $12.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Anthony Vendetti has given his Buy rating due to a combination of factors including Electrocore’s strong financial performance and strategic growth initiatives. The company reported third-quarter 2025 revenue that surpassed both consensus and internal estimates, and it has raised its revenue guidance for 2025, indicating a positive outlook. Electrocore’s expansion in the VA/DoD prescribing facilities, which grew significantly year-over-year, highlights the company’s successful penetration into this market.
Electrocore’s diversified product portfolio, including the legacy gammaCore and the newly acquired Quell Fibromyalgia, is expected to drive revenue growth and reduce customer concentration risk. The company’s strategic investments in expanding its salesforce and marketing efforts across the U.S. are anticipated to sustain its momentum. Furthermore, the management’s guidance for achieving positive adjusted EBITDA in the second half of 2026 and the expectation of reaching cash-flow break-even by 2027 underpin the long-term financial viability of Electrocore. These factors, combined with a compelling valuation, support the Buy rating assigned by Vendetti.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ECOR in relation to earlier this year.